Masking risk of endophthalmitis after intravitreal anti-VEGF injections
October 10th 2021ASRS
During a presentation at American Society of Retina Specialists 2021 annual meeting in San Antonio, Sunir Garg, MD, presented data showing that universal masking does not seem to increase the risk of developing endophthalmitis, and it may cause a reduction in culture positive endophthalmitis.
Determining the time to DME resolution with intravitreal aflibercept
October 9th 2021ASRS
Speaking at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Rishi P. Singh, MD, provided results of the VISTA and VIVID studies, and he pointed out that the findings could help physicians set expectations of DME therapy.
PANORAMA study outlines variables to watch when managing NPDR
October 9th 2021ASRS
During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.
LIGHTSITE II: Photobiomodulation a novel therapy for dry AMD
September 12th 2021EURETINA
During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Study: Better understanding is key to beating diabetes
September 12th 2021EURETINA
In a presentation at the EURETINA 2021 Virtual Conference, Tunde Peto, MD, PhD, pointed out that while complications associated with diabetes develop over a long period, ophthalmologists today have an excellent understanding of diabetes-related eye changes.
Brolucizumab injection offers improved vision in neovascular age-related macular degeneration
September 11th 2021EURETINA
In a presentation at the EURETINA 2021 Virtual Congress, Cristina Cristian, MD, noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Managing retinal folds, role of anterior vitreous in retinal detachments
September 11th 2021EURETINA
Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Gene-independent therapeutic strategies for retinal degeneration include optogenetic therapy
September 10th 2021EURETINA
During a presentation at the EURETINA 2021 Virtual Congress, José-Alain Sahel, MD, explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.
Facing the challenges of treating peripheral hemorrhagic polypoidal choroidal vasculopathy
September 9th 2021EURETINA
Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Chekitaan Singh, MD, discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.